Clinical reference Biomarker Directory
Back to directory

ACP5

Emerging

ACP5/TRAP5b is a bone resorption marker, with an unrelated historical use as a hairy cell leukemia diagnostic marker.

Also known as TRAP5b tartrate-resistant acid phosphatase
In plain language

This enzyme is released when bone is being broken down, so it's used to monitor bone health, similar to other bone tests discussed earlier. A different form of the same enzyme is also a classic, if now largely historical, marker for a specific type of blood cancer called hairy cell leukemia.

Biomarker & context

ACP5 encodes tartrate-resistant acid phosphatase (TRAP), released by osteoclasts during bone resorption; a specific isoform (TRAP5b) serves as a bone resorption marker.

What it indicates

TRAP5b reflects osteoclast activity and bone resorption rate, similar in general role to CTX (discussed earlier), though used somewhat less commonly in routine osteoporosis monitoring; a distinct isoform is also a classic marker for hairy cell leukemia, an unrelated clinical use entirely.

Diagnosis & clinical testing

Measured via serum immunoassay; TRAP5b has the advantage of being less affected by recent food intake than some other bone turnover markers, though CTX and P1NP remain more widely used in standard clinical osteoporosis management.

Guiding treatment

In osteoporosis monitoring, declining TRAP5b supports adequate response to antiresorptive therapy; in hairy cell leukemia, TRAP positivity on tissue staining has historically been a classic diagnostic feature, though it has been substantially supplemented by more specific tests (flow cytometry, BRAF V600E mutation testing) in modern practice.

Clinical significance

Less affected by recent food intake than some other bone turnover markers, though less commonly used than CTX or P1NP.

References
  1. General reference literature on TRAP5b as a bone resorption marker and TRAP staining in hairy cell leukemia diagnosis.